EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Country Contribution to Investigators of Pivotal Clinical Trials and Their Primary Publications of New Drugs Approved by the US Food and Drug Administration, 2012–2021

Yoona Choi iD, Jung-Hyun Won iD, Heeju Kim iD, YeSol Hong iD, Yujin Kim iD, Howard Lee iD

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3589 ↗

At a glance

Journal article in Clinical Pharmacology & Therapeutics, 2025. Written by Yoona Choi and 5 co-authors. Institution: Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea. Major MEDLINE topics: Drug Approval, Clinical Trials as Topic, Research Personnel. 30 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Pivotal clinical trials (PCTs) are often conducted across multiple nations and regions to achieve geographic, racial, or ethnic diversity. However, the diversity of PCT participants remains inadequate. PCTs for new drugs approved by the US Food and Drug Administration in 2012–2021 and their primary publications (PPub) were identified from the label and review documents. The country information about the PCT investigators and PPub authors were extracted from the PPubs or clinicaltrials.gov . The racial/ethnic diversity of PCT participants as reported in PPubs was assessed using the Diversity Index (DI). For 429 new drugs, 734 PCTs and 718 PPubs were identified. North America and Western Europe (NAWE) contributed the largest proportion of PCT investigators, PPub authors, and lead authors (62.9%, 81.7%, and 90.9%, respectively). Of 521 PPubs that reported the racial/ethnic distribution of PCT participants, the median DI was low at 0.33 (interquartile range 0.18–0.46) and only 16.3% PPubs had a DI >0.5. The number of PPub authors in non‐NAWE and the number of countries of PPub authors in non‐NAWE was significantly associated with the racial/ethnic diversity of PCT participants (OR 1.17 [95% CI 1.08–1.26] and OR 1.25 [1.08–1.46], respectively). Evidence generation for the regulatory approval of new drugs has been predominantly centered in NAWE. The dominance is even more pronounced in the authorship of PPubs. To improve the racial/ethnic diversity of PCT participants, investigators from non‐NAWE countries should be encouraged to play more leadership roles, thereby increasing their likelihood of serving as authors in PPub.

Subjects

MeSH terms (MEDLINE)

Drug ApprovalClinical Trials as TopicResearch PersonnelUnited StatesHumansUnited States Food and Drug AdministrationEthnicityEurope

Authors and institutions

  • Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
  • Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
  • Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
  • Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul, Republic of Korea.
  • Advanced Institutes of Convergence Technology, Suwon, Republic of Korea.

ORCID profiles: Yoona Choi, Jung-Hyun Won, Heeju Kim, YeSol Hong, Yujin Kim, Howard Lee

Cite

APA

Choi, Y., Won, J. H., Kim, H., Hong, Y., Kim, Y., & Lee, H. (2025). Country Contribution to Investigators of Pivotal Clinical Trials and Their Primary Publications of New Drugs Approved by the US Food and Drug Administration, 2012–2021. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3589

Vancouver

Choi Y, Won JH, Kim H, Hong Y, Kim Y, Lee H. Country Contribution to Investigators of Pivotal Clinical Trials and Their Primary Publications of New Drugs Approved by the US Food and Drug Administration, 2012–2021. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3589

BibTeX
@article{Choi2025,
  author = {Choi, Yoona and Won, Jung-Hyun and Kim, Heeju and Hong, YeSol and Kim, Yujin and Lee, Howard},
  title = {Country Contribution to Investigators of Pivotal Clinical Trials and Their Primary Publications of New Drugs Approved by the US Food and Drug Administration, 2012–2021},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3589}
}
Start for free →